This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe
6 - 8 June, 2023
Postillon Hotel AmsterdamDigital Experience: All Sessions Live-streamed 6-8 June, 2023

Alain Beck, Ph.D.
Senior Biologics CMC & Developability Director at Pierre Fabre Group

Profile

The current 13 ADCs approved world-wide, targeting hematological malignancies (CD33, CD30, CD22, CD79b, BCMA, CD19) and solid tumors (high or low HER2, Nectin-4, TROP-2, tissue factor, FR alpha) are success benchmarks. In addition, more than 10 are in regulatory review or late-stage clinical trials including site-specific and high-loaded payloads. But near 100 have also failed in clinical trials. Lessons learned will be discussed as well as alternative formats, payloads, linkers, conjugation technologies currently investigated in preclinical or early clinical phases.


Dr Alain Beck is Senior Director, Biologics CMC and Developability (Pierre Fabre), co-founder and Associate Editor of mAbs (2009, https://www.tandfonline.com/journals/kmab20) and chairman of MabDesign SAB (2014, www.mabdesign.fr). He is or was involved in +10 clinical stage biologics R&D programs including dalotuzumab (Merck), telisotuzumab/ telisotuzumab vedotin (AbbVie), lonigutamab ugodotin ADC and W0180 Vista mAb (PF), ER004 Fc-fusion protein (www.esperare.org) and VB421/ lonigutamab (www.valenzabiotech.com). He is author/ co-author of +255 publications (h-index: 63; +14,600 citations). He has contributed to +300 scientific meetings (AET, AIS, BAS, Bioproduction, CASSS, CTDP, EAC, FOB, GlycoBiotec, PEGS, SCT, WADC, WBC, WCBP) as chairman, invited speaker, panellist, moderator, advisor, and/or organizer (IO mAbs, ADCs, Biobetters, Biosimilars, pAbs, Bs/MsAbs, Fc-fusions, Immunocytokines, Protein Scaffolds, Mass Spec, Med Chem, PK/PD, separative sciences). He was ranked 6/50 global antibody industry influencers (2013) and was the 6th WADC (2019) and the 10th AIS Award winner (2022) for long and outstanding contribution in the field. He is member of the MAB Working Party (EDQM/PhEur) and involved in workshops with ANSM, EU, EMA, FDA, NIST, USP and WHO.

Agenda Sessions

  • Co-Chairs’ Remarks

    14:20
  • Current and Next Generation ADCs: Successes and Failures

    14:25